ClinicalTrials.gg
CompletedNCT00272454Updated Dec 16, 2009

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

A Phase 4 interventional study of Cilostazol and Aspirin in Cerebral Infarction, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Completed at 12 sites in Korea, Republic of. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2009-12-16.

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cilostazol in Cerebral Infarction — 1 open to participants now, 1 under way, none of them phase 3. Cilostazol · Cerebral Infarction.

Planned enrollment
6th of 10
468 · median 594
Started
2006
with 1 other
Phase 4
8 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
1 of 10
Korea Otsuka Pharmaceutical Co., Ltd.

Among the 10 studies testing cilostazol in Cerebral Infarction, this one is the 6th largest by planned enrollment, is one of 2 that started in 2006, is one of 8 in phase 4, and was the 4th registered.

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

Browse Cerebral Infarction studies →

Open to participants now

1 of the 10 studies testing cilostazol in Cerebral Infarction is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cilostazol

Cilostazol: first FDA approval 1999 (PLETAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cilostazol in Cerebral Infarction, or all of them as a file.
02

Study summary

The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.

Read the detailed description

Stroke is a leading cause of death and elderly disability in developed countries. However, treatment of acute stroke is limited except thrombolytic therapy in hyperacute stroke within several hours. Currently, aspirin is widely used in spite of its small benefit compared to bleeding complications.

Cilostazol will be compared to aspirin in acute stroke patients in terms of functional outcome at 3 months, efficacy to prevent stroke recurrence, and safety for bleeding complications.

03

Conditions studied

  • Cerebral Infarction

Browse trials for

Keywords

  • cilostazol
  • aspirin
  • cerebral infarction
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who receive explanation on this study and give
  • Patients aged 30 to 85 years
  • Baseline NIHSS less than 15
  • Onset of symptoms within 48 hours of the start of product
  • Full functional independence prior to the present stroke indicated by an mRS score of 0, 1, 2

Exclusion criteria

Exclusion Criteria:

  • Evidence from CT or MRI scan of an acute intracranial hemorrhage, a tumor, encephalitis or any diagnosis other than acute ischemic stroke likely to cause the present symptoms.
  • Previous regular use of an antiplatelet agent or warfarin
  • Patients with known cardiac disease likely to cause cardiogenic embolism or congestive heart failure
  • Evidence from CT or MRI scan of midline shift when visiting hospital
  • Uncontrolled hypertension (SBP>220 mmHg or DBP>120 mmHg)
  • Hypotension (\<90/60 mmHg)
  • Patients with known bleeding diathesis or coagulation disorder
  • Patients with liver disease (>100 or AST>100), or renal disease (creatinine>2.0 mg/dl)
  • Known severe anaemia (\<8.0 mg/dl), or thrombocytopenia (\<100,000/mm3)
  • Scheduled for endarterectomy within 3 months
  • Severe co-morbidity likely to limit patient's to less than 6 months
  • Patients with alcohol or illegal drug abuse or dependency
  • Pregnant or lactating patients. When administrating to females, it should be confirmed that the patients is in the menopause (by evaluation of investigators) or permanently infertile (hysterectomy or surgical operation like bilateral tubal ligation, bilateral oophorectomy, etc). If a patient is likely to be pregnant, the patient should not be pregnant before randomization. And, the patient should use reliable between at least 3 weeks before randomization to 7 days after the final administration of study drug.
  • Patients treated by thrombolytic agents like tPA after onset of stroke
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
468 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Comparison of the frequency of mRS 0, 1, 2 at 90 days

    Time frame: at 90 days

Secondary outcomes

  1. Frequency of mRS 0,1 at 90 days

    Time frame: at 90 days

  2. Frequency of Barthel index 95-100 at 90 days

  3. Frequency of mRS 0,1 & Barthel index 95-100 at 90 days

  4. Frequency of NIHSS 0-1 at 90 days

  5. Frequency of progression of neurological deficit at 7 days (increment of NIHSS 2 points or a point on the item of upper or lower extremity weakness)

  6. Bleeding disorders (life-threatening bleeding; major bleeding; minor Bleeding)

  7. Overall cardiovascular events (Ischemic heart disease requiring rehospitalization)

07

Study locations

12 sites
  • Hallym University Sacred Heart Hospital
    Ahnyang, Kyunggi Province 431-070, Korea, Republic of
  • Inje University Ilsan Paik Hospital
    Koyang, Kyunggi Province 411-706, Korea, Republic of
  • Seoul National University Bundang Hospital
    Sungnam, Kyunggi Province 463-707, Korea, Republic of
  • Eulji University Hospital
    Daejeon, 302-799, Korea, Republic of
  • Inha University Hospital
    Incheon, 400-711, Korea, Republic of
  • Dongguk University Hospital
    Koyang, Kyunggi Province, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-799, Korea, Republic of
  • Hallym University Kangdong Sacred Heart Hospital
    Seoul, 134-701, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • Eulji University Hospital
    Seoul, 139-711, Korea, Republic of
  • Seoul National University Boramae Hospital
    Seoul, 156-707, Korea, Republic of
  • Soonchunhyang University Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC, Kim JS. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011;32(1):65-71. doi: 10.1159/000327036. Epub 2011 May 25. PubMed 21613787 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2006
First posted
Jan 6, 2006
Start
Jan 2006
CompletionActual
Sep 2008
Last update
Dec 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00272454
Collaborators
Seoul National University Boramae Hospital, Korea Otsuka International Asia Arab Co., Ltd.
First posted
Jan 6, 2006
Start date
Jan 2006
Completion
Sep 2008
Last update
Dec 16, 2009

Study contacts

Yong-Seok Lee, M.D., PhD
principal investigator · Department of Neurology, Seoul National University Boramae Hospital, College of Medicine, Seoul National University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion